東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Identification of Small Molecule Inh...

Mullarky, Edouard.

FindBook

Google Book

Amazon

博客來

Identification of Small Molecule Inhibitors of 3-Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancers.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Identification of Small Molecule Inhibitors of 3-Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancers./
作者:	Mullarky, Edouard.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2016,
面頁冊數:	170 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-09(E), Section: B.
Contained By:	Dissertation Abstracts International77-09B(E).
標題:	Cellular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10102877
ISBN:	9781339665054

Identification of Small Molecule Inhibitors of 3-Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancers.
Mullarky, Edouard.

Identification of Small Molecule Inhibitors of 3-Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancers. - Ann Arbor : ProQuest Dissertations & Theses, 2016 - 170 p.

Source: Dissertation Abstracts International, Volume: 77-09(E), Section: B.

Thesis (Ph.D.)--Harvard University, 2016.

This item is not available from ProQuest Dissertations & Theses.

Cancer cells are known to reprogram their metabolism in order to promote growth and proliferation. The amino acid serine is utilized in a plethora of anabolic reactions and supports the synthesis of all three major macromolecular classes: proteins, lipids, and nucleic acids. Serine can either be synthesized de novo via the phosphoserine pathway or imported from the extracellular space via amino acid transporters. The gene encoding the enzyme 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first committed step of the phosphoserine pathway, is focally amplified in human cancers suggesting that it is pro-tumorigenic. Cancer cell lines that harbor PHGDH amplifications, or over express PHGDH independently of amplification, are uniquely sensitive to genetic ablation of the pathway. In contrast, cancer cell lines that express little PHGDH, and instead rely on serine import, are resistant to genetic ablation of the pathway. Given these observations, we speculated that PHGDH might be a clinically interesting target in oncology and sought to develop small molecule inhibitors of PHGDH in order to provide tool compounds with which to study the biology of PHGDH and evaluate the efficacy of inhibiting serine synthesis in cancers.

ISBN: 9781339665054Subjects--Topical Terms:

3172791
Cellular biology.

Identification of Small Molecule Inhibitors of 3-Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancers.
LDR:03158nmm a2200313 4500 001 2123941
005 20171023101701.5
008 180830s2016 ||||||||||||||||| ||eng d
020 $a 9781339665054
035 $a (MiAaPQ)AAI10102877
035 $a AAI10102877
040 $a MiAaPQ $c MiAaPQ
100 1 $a Mullarky, Edouard. $3 3285896
245 1 0 $a Identification of Small Molecule Inhibitors of 3-Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancers.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2016
300 $a 170 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-09(E), Section: B.
500 $a Adviser: Sheila Thomas.
502 $a Thesis (Ph.D.)--Harvard University, 2016.
506 $a This item is not available from ProQuest Dissertations & Theses.
520 $a Cancer cells are known to reprogram their metabolism in order to promote growth and proliferation. The amino acid serine is utilized in a plethora of anabolic reactions and supports the synthesis of all three major macromolecular classes: proteins, lipids, and nucleic acids. Serine can either be synthesized de novo via the phosphoserine pathway or imported from the extracellular space via amino acid transporters. The gene encoding the enzyme 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first committed step of the phosphoserine pathway, is focally amplified in human cancers suggesting that it is pro-tumorigenic. Cancer cell lines that harbor PHGDH amplifications, or over express PHGDH independently of amplification, are uniquely sensitive to genetic ablation of the pathway. In contrast, cancer cell lines that express little PHGDH, and instead rely on serine import, are resistant to genetic ablation of the pathway. Given these observations, we speculated that PHGDH might be a clinically interesting target in oncology and sought to develop small molecule inhibitors of PHGDH in order to provide tool compounds with which to study the biology of PHGDH and evaluate the efficacy of inhibiting serine synthesis in cancers.
520 $a In order to identify inhibitors of PHGDH an in vitro enzymatic assay was developed and libraries of drug-like small molecules were screened. Hit compounds were validated in biochemical assays to determine potency and selectivity for PHGDH. Selected compounds were tested on cells for their ability to inhibit de novo serine synthesis and one lead, CBR-5884, was identified. CBR-5884 was selectively toxic to PHGDH amplified or overexpressing cancer cells but had no effect on cells that express little PHGDH. Mechanistically, CBR-5884 was found to be a non-competitive inhibitor that showed a time dependent onset of inhibition and disrupted the oligomerization state of PHGDH. These results provide a proof-of-concept for targeting PHGDH and suggest that inhibiting PHGDH in cancers addicted to serine synthesis is a potentially viable targeted therapy option.
590 $a School code: 0084.
650 4 $a Cellular biology. $3 3172791
650 4 $a Biochemistry. $3 518028
690 $a 0379
690 $a 0487
710 2 $a Harvard University. $b Medical Sciences. $3 3181716
773 0 $t Dissertation Abstracts International $g 77-09B(E).
790 $a 0084
791 $a Ph.D.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10102877